Outcome of patients with chlorpyrifos intoxication

Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human & experimental toxicology 2020-10, Vol.39 (10), p.1291-1300
Hauptverfasser: Liu, H-F, Ku, C-H, Chang, S-S, Chang, C-M, Wang, I-K, Yang, H-Y, Weng, C-H, Huang, W-H, Hsu, C-W, Yen, T-H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1300
container_issue 10
container_start_page 1291
container_title Human & experimental toxicology
container_volume 39
creator Liu, H-F
Ku, C-H
Chang, S-S
Chang, C-M
Wang, I-K
Yang, H-Y
Weng, C-H
Huang, W-H
Hsu, C-W
Yen, T-H
description Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis. Results: Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified. Conclusion: The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.
doi_str_mv 10.1177/0960327120920911
format Article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_journals_2429086529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327120920911</sage_id><sourcerecordid>2429086529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</originalsourceid><addsrcrecordid>eNp1kN1LwzAUxYMobk7ffZKCz9V7kyZpHmX4BYO97L2kTeI6tqYmLbr_3o5OBUG4cB_O75wDh5BrhDtEKe9BCWBUIgU1HOIJmWImZQoK2CmZHuT0oE_IRYwbABCK4zmZMMqYQM6nhC77rvI7m3iXtLqrbdPF5KPu1km13vrQ7kPtfEzqpvOfdTUAvrkkZ05vo706_hlZPT2u5i_pYvn8On9YpBUTvEuRGmNKkyN3oBxTpeACrNOVMwK11TS3lc05laV0BnIppKY0G0A01GLGZuR2jG2Df-9t7IqN70MzNBY0owpywakaKBipKvgYg3VFG-qdDvsCoThsVPzdaLDcHIP7cmfNj-F7lAFIRyDqN_vb-m_gF7jlbb8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429086529</pqid></control><display><type>article</type><title>Outcome of patients with chlorpyrifos intoxication</title><source>Sage Journals GOLD Open Access 2024</source><creator>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</creator><creatorcontrib>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</creatorcontrib><description>Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis. Results: Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified. Conclusion: The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327120920911</identifier><identifier>PMID: 32336155</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Atropine ; Blood ; Chlorpyrifos ; Chlorpyrifos - toxicity ; Cholinergics ; Cholinesterase Inhibitors - toxicity ; Cholinesterase Reactivators - therapeutic use ; Coma ; Complications ; Confidence intervals ; Female ; Humans ; Insecticides - toxicity ; Intoxication ; Kidneys ; Male ; Middle Aged ; Monocytes ; Mortality ; Neuropathy ; Nitrogen ; Patients ; Pesticides ; Pralidoxime Compounds - therapeutic use ; Prognosis ; Regression analysis ; Regression models ; Renal failure ; Respiratory failure ; Retrospective Studies ; Risk analysis ; Risk factors ; Seizures ; Statistical analysis ; Subgroups ; Tachycardia ; Urea ; Vomiting</subject><ispartof>Human &amp; experimental toxicology, 2020-10, Vol.39 (10), p.1291-1300</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</citedby><cites>FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</cites><orcidid>0000-0002-0907-1505</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327120920911$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327120920911$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21957,27844,27915,27916,44936,45324</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327120920911?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32336155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, H-F</creatorcontrib><creatorcontrib>Ku, C-H</creatorcontrib><creatorcontrib>Chang, S-S</creatorcontrib><creatorcontrib>Chang, C-M</creatorcontrib><creatorcontrib>Wang, I-K</creatorcontrib><creatorcontrib>Yang, H-Y</creatorcontrib><creatorcontrib>Weng, C-H</creatorcontrib><creatorcontrib>Huang, W-H</creatorcontrib><creatorcontrib>Hsu, C-W</creatorcontrib><creatorcontrib>Yen, T-H</creatorcontrib><title>Outcome of patients with chlorpyrifos intoxication</title><title>Human &amp; experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis. Results: Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified. Conclusion: The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</description><subject>Adult</subject><subject>Aged</subject><subject>Atropine</subject><subject>Blood</subject><subject>Chlorpyrifos</subject><subject>Chlorpyrifos - toxicity</subject><subject>Cholinergics</subject><subject>Cholinesterase Inhibitors - toxicity</subject><subject>Cholinesterase Reactivators - therapeutic use</subject><subject>Coma</subject><subject>Complications</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Humans</subject><subject>Insecticides - toxicity</subject><subject>Intoxication</subject><subject>Kidneys</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Mortality</subject><subject>Neuropathy</subject><subject>Nitrogen</subject><subject>Patients</subject><subject>Pesticides</subject><subject>Pralidoxime Compounds - therapeutic use</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Regression models</subject><subject>Renal failure</subject><subject>Respiratory failure</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Seizures</subject><subject>Statistical analysis</subject><subject>Subgroups</subject><subject>Tachycardia</subject><subject>Urea</subject><subject>Vomiting</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kN1LwzAUxYMobk7ffZKCz9V7kyZpHmX4BYO97L2kTeI6tqYmLbr_3o5OBUG4cB_O75wDh5BrhDtEKe9BCWBUIgU1HOIJmWImZQoK2CmZHuT0oE_IRYwbABCK4zmZMMqYQM6nhC77rvI7m3iXtLqrbdPF5KPu1km13vrQ7kPtfEzqpvOfdTUAvrkkZ05vo706_hlZPT2u5i_pYvn8On9YpBUTvEuRGmNKkyN3oBxTpeACrNOVMwK11TS3lc05laV0BnIppKY0G0A01GLGZuR2jG2Df-9t7IqN70MzNBY0owpywakaKBipKvgYg3VFG-qdDvsCoThsVPzdaLDcHIP7cmfNj-F7lAFIRyDqN_vb-m_gF7jlbb8</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Liu, H-F</creator><creator>Ku, C-H</creator><creator>Chang, S-S</creator><creator>Chang, C-M</creator><creator>Wang, I-K</creator><creator>Yang, H-Y</creator><creator>Weng, C-H</creator><creator>Huang, W-H</creator><creator>Hsu, C-W</creator><creator>Yen, T-H</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>SOI</scope><orcidid>https://orcid.org/0000-0002-0907-1505</orcidid></search><sort><creationdate>202010</creationdate><title>Outcome of patients with chlorpyrifos intoxication</title><author>Liu, H-F ; Ku, C-H ; Chang, S-S ; Chang, C-M ; Wang, I-K ; Yang, H-Y ; Weng, C-H ; Huang, W-H ; Hsu, C-W ; Yen, T-H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-12dddbd815f09f39b6560efacfd61aea28ece8527b7fd08767a224f391d2e143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atropine</topic><topic>Blood</topic><topic>Chlorpyrifos</topic><topic>Chlorpyrifos - toxicity</topic><topic>Cholinergics</topic><topic>Cholinesterase Inhibitors - toxicity</topic><topic>Cholinesterase Reactivators - therapeutic use</topic><topic>Coma</topic><topic>Complications</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Humans</topic><topic>Insecticides - toxicity</topic><topic>Intoxication</topic><topic>Kidneys</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Mortality</topic><topic>Neuropathy</topic><topic>Nitrogen</topic><topic>Patients</topic><topic>Pesticides</topic><topic>Pralidoxime Compounds - therapeutic use</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Regression models</topic><topic>Renal failure</topic><topic>Respiratory failure</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Seizures</topic><topic>Statistical analysis</topic><topic>Subgroups</topic><topic>Tachycardia</topic><topic>Urea</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, H-F</creatorcontrib><creatorcontrib>Ku, C-H</creatorcontrib><creatorcontrib>Chang, S-S</creatorcontrib><creatorcontrib>Chang, C-M</creatorcontrib><creatorcontrib>Wang, I-K</creatorcontrib><creatorcontrib>Yang, H-Y</creatorcontrib><creatorcontrib>Weng, C-H</creatorcontrib><creatorcontrib>Huang, W-H</creatorcontrib><creatorcontrib>Hsu, C-W</creatorcontrib><creatorcontrib>Yen, T-H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environment Abstracts</collection><jtitle>Human &amp; experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Liu, H-F</au><au>Ku, C-H</au><au>Chang, S-S</au><au>Chang, C-M</au><au>Wang, I-K</au><au>Yang, H-Y</au><au>Weng, C-H</au><au>Huang, W-H</au><au>Hsu, C-W</au><au>Yen, T-H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of patients with chlorpyrifos intoxication</atitle><jtitle>Human &amp; experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>39</volume><issue>10</issue><spage>1291</spage><epage>1300</epage><pages>1291-1300</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>Introduction: There is a paucity of literature analyzing outcome of chlorpyrifos intoxication. Methods: A total of 40 patients with chlorpyrifos intoxication were seen at Chang Gung Memorial Hospital between 2008 and 2017. Patients were stratified into two subgroups according to their prognosis, as good (n = 12) or poor (n = 28). Good prognosis group were defined as patients who survived without serious complications, and poor prognosis group included patients who died and survived after development of severe complications. Demographic, clinical, laboratory, and mortality data were obtained for analysis. Results: Patients aged 53.8 ± 16.3 years and most were male (80.0%). All patients (100.0%) developed acute cholinergic crisis such as emesis (45.0%), respiratory failure (42.5%), tachycardia (30.0%), kidney injury (22.5%), and seizure (7.5%). Intermediate syndrome developed in 12.5% of patients, but none had delayed neuropathy (0%). The poor prognosis group suffered higher incidences of respiratory failure (p = 0.011), kidney injury (p = 0.026), and prolonged corrected QT interval (p = 0.000), and they had higher blood urea nitrogen level (p = 0.041), lower Glasgow coma scale score (p = 0.011), and lower monocyte count (p = 0.023) than good prognosis group. All patients were treated with atropine and pralidoxime therapy, but six patients (15.0%) still died of intoxication. In a multivariate logistic regression model, blood urea nitrogen was a significant risk factor for poor prognosis (odds ratio: 1.375, 95% confidence interval: 1.001–1.889, p = 0.049). Nevertheless, no mortality risk factor could be identified. Conclusion: The mortality rate of patients with chlorpyrifos intoxication was 15.0%. Furthermore, acute cholinergic crisis, intermediate syndrome, and delayed neuropathy developed in 100.0%, 12.5%, and 0% of patients, respectively.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32336155</pmid><doi>10.1177/0960327120920911</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-0907-1505</orcidid></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0960-3271
ispartof Human & experimental toxicology, 2020-10, Vol.39 (10), p.1291-1300
issn 0960-3271
1477-0903
language eng
recordid cdi_proquest_journals_2429086529
source Sage Journals GOLD Open Access 2024
subjects Adult
Aged
Atropine
Blood
Chlorpyrifos
Chlorpyrifos - toxicity
Cholinergics
Cholinesterase Inhibitors - toxicity
Cholinesterase Reactivators - therapeutic use
Coma
Complications
Confidence intervals
Female
Humans
Insecticides - toxicity
Intoxication
Kidneys
Male
Middle Aged
Monocytes
Mortality
Neuropathy
Nitrogen
Patients
Pesticides
Pralidoxime Compounds - therapeutic use
Prognosis
Regression analysis
Regression models
Renal failure
Respiratory failure
Retrospective Studies
Risk analysis
Risk factors
Seizures
Statistical analysis
Subgroups
Tachycardia
Urea
Vomiting
title Outcome of patients with chlorpyrifos intoxication
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T21%3A17%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20patients%20with%20chlorpyrifos%20intoxication&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Liu,%20H-F&rft.date=2020-10&rft.volume=39&rft.issue=10&rft.spage=1291&rft.epage=1300&rft.pages=1291-1300&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327120920911&rft_dat=%3Cproquest_AFRWT%3E2429086529%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2429086529&rft_id=info:pmid/32336155&rft_sage_id=10.1177_0960327120920911&rfr_iscdi=true